These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 28063616)

  • 1. Chitinase 3-like 1 is associated with the response to interferon-beta treatment in multiple sclerosis.
    Matute-Blanch C; Río J; Villar LM; Midaglia L; Malhotra S; Álvarez-Cermeño JC; Vidal-Jordana A; Montalban X; Comabella M
    J Neuroimmunol; 2017 Feb; 303():62-65. PubMed ID: 28063616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of apoptosis in CD4(+) T-cells is linked with optimal treatment response in patients with relapsing-remitting multiple sclerosis treated with Glatiramer acetate.
    Boziki M; Lagoudaki R; Melo P; Kanidou F; Bakirtzis C; Nikolaidis I; Grigoriadou E; Afrantou T; Tatsi T; Matsi S; Grigoriadis N
    J Neurol Sci; 2019 Jun; 401():43-50. PubMed ID: 31009931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different clinical response to interferon beta and glatiramer acetate related to the presence of oligoclonal IgM bands in CSF in multiple sclerosis patients.
    Casanova B; Lacruz L; Villar ML; Domínguez JA; Gadea MC; Gascón F; Mallada J; Hervás D; Simó-Castelló M; Álvarez-Cermeño JC; Calles C; Olascoaga J; Ramió-Torrentà L; Alcalá C; Cervelló A; Boscá I; Pérez-Mirallles FC; Coret F
    Neurol Sci; 2018 Aug; 39(8):1423-1430. PubMed ID: 29882169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy.
    Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
    Mult Scler; 2001 Dec; 7(6):349-53. PubMed ID: 11795454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive cytokine biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis.
    Valenzuela RM; Kaufman M; Balashov KE; Ito K; Buyske S; Dhib-Jalbut S
    J Neuroimmunol; 2016 Nov; 300():59-65. PubMed ID: 27390072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon β-1b and glatiramer acetate effects on permanent black hole evolution.
    Filippi M; Rocca MA; Camesasca F; Cook S; O'Connor P; Arnason BG; Kappos L; Goodin D; Jeffery D; Hartung HP; Comi G; Wolinsky JS; Bogumil T; Pohl C; Beckmann K; Sandbrink R; Croze E; Brown C; Desimone TM; Arnold DL; Cutter G; Knappertz V
    Neurology; 2011 Apr; 76(14):1222-8. PubMed ID: 21464426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chitinase 3-like 1 plasma levels are increased in patients with progressive forms of multiple sclerosis.
    Cantó E; Reverter F; Morcillo-Suárez C; Matesanz F; Fernández O; Izquierdo G; Vandenbroeck K; Rodríguez-Antigüedad A; Urcelay E; Arroyo R; Otaegui D; Olascoaga J; Saiz A; Navarro A; Sanchez A; Domínguez C; Caminero A; Horga A; Tintoré M; Montalban X; Comabella M
    Mult Scler; 2012 Jul; 18(7):983-90. PubMed ID: 22183936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
    Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
    Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of immunomodulatory therapy with interferon-β or glatiramer acetate on multiple sclerosis-associated uveitis.
    Velazquez-Villoria D; Macia-Badia C; Segura-García A; Pastor Idoate S; Arcos-Algaba G; Velez-Escola L; García-Arumí J
    Arch Soc Esp Oftalmol; 2017 Jun; 92(6):273-279. PubMed ID: 28188020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the response to glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS) patients.
    Río J; Rovira A; Tintoré M; Sastre-Garriga J; Castilló J; Auger C; Nos C; Comabella M; Tur C; Vidal Á; Montalbán X
    Mult Scler; 2014 Oct; 20(12):1602-8. PubMed ID: 24622350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of combined IFNbeta-1a and glatiramer acetate therapy on GA-specific T-cell responses in multiple sclerosis.
    Dhib-Jalbut S; Chen M; Henschel K; Ford D; Costello K; Panitch H
    Mult Scler; 2002 Dec; 8(6):485-91. PubMed ID: 12474988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alterations in serum levels of IL-17 in contrast to TNF-alpha correspond to disease-modifying treatment in relapsing-remitting multiple sclerosis.
    Trenova AG; Slavov GS; Manova MG; Draganaova-Filipova MN; Mateva NG; Miteva LD; Stanilova SA
    Scand J Clin Lab Invest; 2017 Jul; 77(4):283-288. PubMed ID: 28319417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 12-months prospective Pentraxin-3 and metabolomic evaluation in multiple sclerosis patients treated with glatiramer acetate.
    Signoriello E; Iardino P; Casertano S; De Lucia D; Pucciarelli A; Puoti G; Chiosi E; Lus G
    J Neuroimmunol; 2020 Nov; 348():577385. PubMed ID: 32927398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B-Cell Activity Predicts Response to Glatiramer Acetate and Interferon in Relapsing-Remitting Multiple Sclerosis.
    Tacke S; Braune S; Rovituso DM; Ziemssen T; Lehmann PV; Dikow H; Bergmann A; Kuerten S
    Neurol Neuroimmunol Neuroinflamm; 2021 May; 8(3):. PubMed ID: 33707177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical response to interferon beta and glatiramer acetate in multiple sclerosis patients: a Brazilian cohort.
    Pereira VC; Malfetano FR; Meira ID; Souza LF; Liem AM; Maiolino A; Alves-Leon SV
    Arq Neuropsiquiatr; 2012 Oct; 70(10):774-9. PubMed ID: 23060103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-27: a potential biomarker for responders to glatiramer acetate therapy.
    Mindur JE; Valenzuela RM; Yadav SK; Boppana S; Dhib-Jalbut S; Ito K
    J Neuroimmunol; 2017 Mar; 304():21-28. PubMed ID: 27449853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effectiveness of interferon beta versus glatiramer acetate and natalizumab versus fingolimod in a Polish real-world population.
    Kapica-Topczewska K; Tarasiuk J; Collin F; Brola W; Chorąży M; Czarnowska A; Kwaśniewski M; Bartosik-Psujek H; Adamczyk-Sowa M; Kochanowicz J; Kułakowska A
    PLoS One; 2019; 14(10):e0223863. PubMed ID: 31647829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SIRT1 as a potential biomarker of response to treatment with glatiramer acetate in multiple sclerosis.
    Hewes D; Tatomir A; Kruszewski AM; Rao G; Tegla CA; Ciriello J; Nguyen V; Royal W; Bever C; Rus V; Rus H
    Exp Mol Pathol; 2017 Apr; 102(2):191-197. PubMed ID: 28109694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of first-line treatment persistence in a Portuguese cohort of relapsing-remitting multiple sclerosis.
    Correia I; Marques IB; Sousa M; Batista S; Ferreira R; Nunes C; Macário C; Cunha L; Sousa L
    J Clin Neurosci; 2016 Nov; 33():73-78. PubMed ID: 27542939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States.
    Hernandez L; Guo S; Kinter E; Fay M
    J Med Econ; 2016 Jul; 19(7):684-95. PubMed ID: 26947984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.